SIMCERE PHARMA (02096) · Company profile · Eqvero

SIMCERE PHARMA

02096HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	7.73 bn CNY	6.64 bn CNY	6.61 bn CNY	6.32 bn CNY	5 bn CNY
Cost of revenue	1.04 bn CNY	1.01 bn CNY	1.33 bn CNY	1.05 bn CNY	845.59 m CNY
Research and development expense	1.56 bn CNY	1.45 bn CNY	1.58 bn CNY	1.74 bn CNY	1.43 bn CNY
Selling, general and administrative expense	3.51 bn CNY	3.04 bn CNY	2.86 bn CNY	2.85 bn CNY	2.42 bn CNY
Operating profit after depreciation	1.42 bn CNY	1.13 bn CNY	710.84 m CNY	608.24 m CNY	233.33 m CNY
Operating profit before depreciation	1.8 bn CNY	1.43 bn CNY	1 bn CNY	876.18 m CNY	467.72 m CNY
EBIT	1.42 bn CNY	1.13 bn CNY	710.84 m CNY	608.24 m CNY	233.33 m CNY
EBITDA	1.8 bn CNY	1.43 bn CNY	1 bn CNY	876.18 m CNY	467.72 m CNY
Interest expense	95.8 m CNY	69.56 m CNY	34.57 m CNY	34.41 m CNY	70.85 m CNY
Profit before tax	1.51 bn CNY	819.88 m CNY	740.04 m CNY	888.15 m CNY	1.4 bn CNY
Income tax expense	170.32 m CNY	86.71 m CNY	26.09 m CNY	-40.48 m CNY	-97.12 m CNY
Income before extraordinary items	1.34 bn CNY	733.17 m CNY	714.76 m CNY	932.77 m CNY	1.51 bn CNY
Common dividends	467.23 m CNY	397.81 m CNY	418.68 m CNY	425.66 m CNY	394.24 m CNY
Total dividends	467.23 m CNY	397.81 m CNY	418.68 m CNY	425.66 m CNY	394.24 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.